Individuals who have cirrhosis but no concurrent malignancies, as well as those with varying BCLC stages of hepatocellular carcinoma patients (stages 0-D)
Conditions
Interventions
participants with cirrhosis without hepatocellular carcinoma, participants with BCLC staging 0-D:without involving
Sponsors
Affiliated Hospital of Chengdu University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Age 18 to 70; 1.Patients meet the European Association for the Study of the Liver (EASL) 2018 diagnostic criteria (EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma), which require that the clinical diagnosis of HCC can be established when two of the following conditions are simultaneously met: (i) evidence of cirrhosis and HBV and/or HCV infection (HBV and/or HCV antigen); (ii) typical imaging of HCC. The clinical diagnosis of HCC can be established by: (1) evidence of cirrhosis and HBV and/or HCV infection (HBV and/or HCV antigen-positive); (2) typical imaging features of HCC: rapid heterogeneous vascular enhancement of hepatic occupations in the arterial phase with rapid elution in the venous or delayed phases on multislice CT scanning and/or dynamic contrast-enhanced MRI; and (3) a fast elution of the hepatic occupation in the venous or delayed phases. 2cm in diameter, one of the two imaging tests, CT and MRI, shows that the liver occupancy has the characteristics of hepatocellular carcinoma as described above, then the diagnosis of HCC can be made. b If the diameter of the liver occupancy is 1-2cm, both CT and MRI imaging tests need to show that the liver occupancy has the characteristics of hepatocellular carcinoma as described above, then the diagnosis of HCC can be made, in order to enhance the diagnostic specificity. c) serum AFP = 400 µg/L lasting for 1 month or = 200 µg/L lasting for 1 month or = 200 µg/L lasting for 2 months. (iii) Serum AFP =400µg/L for 1 month or =200µg/L for 2 months, and other causes of AFP elevation can be ruled out, including pregnancy, germline embryonic tumors, active liver disease and secondary hepatocellular carcinoma; 2.Cirrhotic patients met the European Association for the Study of the Liver (EASL) 2018 diagnostic criteria (EASL Clinical Practice Guidelines on non-invasive tests forevaluation of liver disease severity and prognosis - 2021 update), specifically, if liver histopathology is not performed, cirrhosis can be clinically diagnosed if more than 2 of the following 5 items are met and non-cirrhotic portal hypertension is excluded: ? Gastroscopy shows esophagogastric venous varices; ? Imaging: ultrasonography, CT, or MRI have imaging features of cirrhosis; ? Liver elastometry: LSM > 13 kPa; ? Liver synthetic Liver synthesis: decrease in serum albumin, prolongation of prothrombin time; ? hypersplenism: decrease in platelets, white blood cells or hemoglobin, etc; 3.Complete clinical data, such as tumor markers, tumor size, morphology, blood biochemistry, imaging, and other relevant information; 4.Participants without significant heart, brain, lung, kidney, or other organ disease.
Exclusion criteria
Exclusion criteria: 1.Subjects have been definitively diagnosed and treated for primary liver cancer; 2.Subjects having metastatic liver cancers and a mix of additional tumors; 3.Subjects having incomplete clinical data; 4.Subjects having a clinical diagnosis of cirrhosis combined with a tumor;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| without involving;Peripheral blood immune infiltration status; | — |
Countries
China
Contacts
Public ContactXiangke Niu
Affiliated Hospital of Chengdu University
Outcome results
None listed